Litcius/Paper detail

Design, synthesis, and antitumor activity of novel benzoheterocycle derivatives as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase

Yangyang Ding, Kai Liu, Xinyu Zhao, Yingtao Lv, Rilei Yu, Congmin Kang

2020Journal of Chemical Research13 citationsDOIOpen Access PDF

Abstract

The vascular endothelial growth factor receptor-2 signaling pathway promotes the formation of new blood vessels, and vascular endothelial growth factor receptor-2 tyrosine kinase exists in both active and inactive conformations. Novel indole–benzimidazole and indole–benzothiazole derivatives joined by different linkers are designed and synthesized as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase. All the synthesized compounds were evaluated for their cytotoxicity against four human cancer cell lines (HeLa, HT29, A549, and MDA-MB-435) and human umbilical vein endothelial cell. Meanwhile, the inhibitory activities against vascular endothelial growth factor receptor-2 are estimated in vitro and the binding interactions with dual conformations of vascular endothelial growth factor receptor-2 tyrosine kinase are evaluated by molecular docking. Compounds 5a–c and 14 show inhibitory activity against vascular endothelial growth factor receptor-2 tyrosine kinase and promising cytotoxicity, specifically with IC 50 values ranging between 0.1 and 1 μM, which imply broad-spectrum antitumor activity. These results provide a deep insight into potential structural modifications for developing potent vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.

Topics & Concepts

Kinase insert domain receptorVascular endothelial growth factorReceptor tyrosine kinaseVascular endothelial growth factor AVascular endothelial growth factor BTyrosine kinaseTropomyosin receptor kinase CVascular endothelial growth factor CPlatelet-derived growth factor receptorVascular endothelial growth inhibitorChemistryBiologyCell biologyCancer researchBiochemistryReceptorSignal transductionGrowth factorVEGF receptorsAngiogenesis and VEGF in CancerChronic Myeloid Leukemia TreatmentsHER2/EGFR in Cancer Research